6.58 USD
+0.07 (+1.08%)
6.58 USD
0 (0%)
Taking everything into account, NAGE scores 7 out of 10 in our fundamental rating. NAGE was compared to 57 industry peers in the Life Sciences Tools & Services industry. NAGE has an excellent financial health rating, but there are some minor concerns on its profitability. NAGE is growing strongly while it is still valued neutral. This is a good combination! With these ratings, NAGE could be worth investigating further for growth investing!.
1. Profitability
1.1 Basic Checks
In the past year NAGE was profitable.
In the past year NAGE had a positive cash flow from operations.
In the past 5 years NAGE reported 4 times negative net income.
The reported operating cash flow has been mixed in the past 5 years: NAGE reported negative operating cash flow in multiple years.
1.2 Ratios
NAGE's Return On Assets of 20.82% is amongst the best of the industry. NAGE outperforms 96.49% of its industry peers.
Looking at the Return On Equity, with a value of 28.91%, NAGE belongs to the top of the industry, outperforming 94.74% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 20.22%, NAGE belongs to the top of the industry, outperforming 94.74% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.82% | ||
| ROE | 28.91% | ||
| ROIC | 20.22% |
ROA(3y)-9.02%
ROA(5y)-25.18%
ROE(3y)-18.83%
ROE(5y)-52.67%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 16.38%, NAGE belongs to the top of the industry, outperforming 87.72% of the companies in the same industry.
NAGE has a Operating Margin of 15.48%. This is in the better half of the industry: NAGE outperforms 78.95% of its industry peers.
The Gross Margin of NAGE (63.89%) is better than 84.21% of its industry peers.
NAGE's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 15.48% | ||
| PM (TTM) | 16.38% | ||
| GM | 63.89% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y2.12%
2. Health
2.1 Basic Checks
NAGE has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for NAGE has been increased compared to 1 year ago.
The number of shares outstanding for NAGE has been increased compared to 5 years ago.
Compared to 1 year ago, NAGE has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 11.73 indicates that NAGE is not in any danger for bankruptcy at the moment.
The Altman-Z score of NAGE (11.73) is better than 96.49% of its industry peers.
NAGE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 11.73 |
ROIC/WACC1.93
WACC10.46%
2.3 Liquidity
A Current Ratio of 4.12 indicates that NAGE has no problem at all paying its short term obligations.
NAGE's Current ratio of 4.12 is fine compared to the rest of the industry. NAGE outperforms 64.91% of its industry peers.
NAGE has a Quick Ratio of 3.29. This indicates that NAGE is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 3.29, NAGE is doing good in the industry, outperforming 66.67% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.12 | ||
| Quick Ratio | 3.29 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 2300.00% over the past year.
NAGE shows a strong growth in Revenue. In the last year, the Revenue has grown by 36.04%.
The Revenue has been growing by 16.56% on average over the past years. This is quite good.
EPS 1Y (TTM)2300%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%150%
Revenue 1Y (TTM)36.04%
Revenue growth 3Y13.87%
Revenue growth 5Y16.56%
Sales Q2Q%32.86%
3.2 Future
The Earnings Per Share is expected to grow by 59.22% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 22.85% on average over the next years. This is a very strong growth
EPS Next Y85.64%
EPS Next 2Y73.46%
EPS Next 3Y64.95%
EPS Next 5Y59.22%
Revenue Next Year30.96%
Revenue Next 2Y25.55%
Revenue Next 3Y23.66%
Revenue Next 5Y22.85%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
NAGE is valuated quite expensively with a Price/Earnings ratio of 27.42.
Based on the Price/Earnings ratio, NAGE is valued a bit cheaper than 77.19% of the companies in the same industry.
NAGE's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 26.59.
With a Price/Forward Earnings ratio of 21.87, NAGE is valued on the expensive side.
Based on the Price/Forward Earnings ratio, NAGE is valued cheaper than 82.46% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 23.80. NAGE is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 27.42 | ||
| Fwd PE | 21.87 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of NAGE indicates a somewhat cheap valuation: NAGE is cheaper than 73.68% of the companies listed in the same industry.
NAGE's Price/Free Cash Flow ratio is rather cheap when compared to the industry. NAGE is cheaper than 80.70% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 24.83 | ||
| EV/EBITDA | 22.68 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of NAGE may justify a higher PE ratio.
NAGE's earnings are expected to grow with 64.95% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.32
PEG (5Y)N/A
EPS Next 2Y73.46%
EPS Next 3Y64.95%
5. Dividend
5.1 Amount
No dividends for NAGE!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
6.58
+0.07 (+1.08%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners41.1%
Inst Owner ChangeN/A
Ins Owners0.01%
Ins Owner Change0.43%
Market Cap525.15M
Revenue(TTM)124.71M
Net Income(TTM)20.43M
Analysts85.45
Price Target16.12 (144.98%)
Short Float %10.7%
Short Ratio5.14
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)193.24%
Min EPS beat(2)180.11%
Max EPS beat(2)206.37%
EPS beat(4)4
Avg EPS beat(4)245.13%
Min EPS beat(4)180.11%
Max EPS beat(4)341.18%
EPS beat(8)8
Avg EPS beat(8)213.82%
EPS beat(12)12
Avg EPS beat(12)154.96%
EPS beat(16)14
Avg EPS beat(16)118.55%
Revenue beat(2)2
Avg Revenue beat(2)7.42%
Min Revenue beat(2)7.13%
Max Revenue beat(2)7.71%
Revenue beat(4)4
Avg Revenue beat(4)7.98%
Min Revenue beat(4)6.81%
Max Revenue beat(4)10.27%
Revenue beat(8)5
Avg Revenue beat(8)2.84%
Revenue beat(12)7
Avg Revenue beat(12)2.74%
Revenue beat(16)7
Avg Revenue beat(16)0.15%
PT rev (1m)-1.5%
PT rev (3m)-1.5%
EPS NQ rev (1m)-8.33%
EPS NQ rev (3m)-8.33%
EPS NY rev (1m)26.39%
EPS NY rev (3m)35.82%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-5.92%
Revenue NY rev (1m)0.66%
Revenue NY rev (3m)1.49%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 27.42 | ||
| Fwd PE | 21.87 | ||
| P/S | 4.21 | ||
| P/FCF | 24.83 | ||
| P/OCF | 24.53 | ||
| P/B | 7.43 | ||
| P/tB | 7.46 | ||
| EV/EBITDA | 22.68 |
EPS(TTM)0.24
EY3.65%
EPS(NY)0.3
Fwd EY4.57%
FCF(TTM)0.26
FCFY4.03%
OCF(TTM)0.27
OCFY4.08%
SpS1.56
BVpS0.89
TBVpS0.88
PEG (NY)0.32
PEG (5Y)N/A
Graham Number2.19
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.82% | ||
| ROE | 28.91% | ||
| ROCE | 25.59% | ||
| ROIC | 20.22% | ||
| ROICexc | 135.09% | ||
| ROICexgc | 138.1% | ||
| OM | 15.48% | ||
| PM (TTM) | 16.38% | ||
| GM | 63.89% | ||
| FCFM | 16.96% |
ROA(3y)-9.02%
ROA(5y)-25.18%
ROE(3y)-18.83%
ROE(5y)-52.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y2.12%
F-Score7
Asset Turnover1.27
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 33.55% | ||
| Cap/Sales | 0.21% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 106.62% | ||
| Profit Quality | 103.52% | ||
| Current Ratio | 4.12 | ||
| Quick Ratio | 3.29 | ||
| Altman-Z | 11.73 |
F-Score7
WACC10.46%
ROIC/WACC1.93
Cap/Depr(3y)21.85%
Cap/Depr(5y)22.95%
Cap/Sales(3y)0.27%
Cap/Sales(5y)0.33%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)2300%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%150%
EPS Next Y85.64%
EPS Next 2Y73.46%
EPS Next 3Y64.95%
EPS Next 5Y59.22%
Revenue 1Y (TTM)36.04%
Revenue growth 3Y13.87%
Revenue growth 5Y16.56%
Sales Q2Q%32.86%
Revenue Next Year30.96%
Revenue Next 2Y25.55%
Revenue Next 3Y23.66%
Revenue Next 5Y22.85%
EBIT growth 1Y4218.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year965.72%
EBIT Next 3Y173.71%
EBIT Next 5YN/A
FCF growth 1Y262.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y248.66%
OCF growth 3YN/A
OCF growth 5YN/A
NIAGEN BIOSCIENCE INC / NAGE FAQ
What is the fundamental rating for NAGE stock?
ChartMill assigns a fundamental rating of 7 / 10 to NAGE.
What is the valuation status for NAGE stock?
ChartMill assigns a valuation rating of 6 / 10 to NIAGEN BIOSCIENCE INC (NAGE). This can be considered as Fairly Valued.
What is the profitability of NAGE stock?
NIAGEN BIOSCIENCE INC (NAGE) has a profitability rating of 6 / 10.
What is the valuation of NIAGEN BIOSCIENCE INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for NIAGEN BIOSCIENCE INC (NAGE) is 27.42 and the Price/Book (PB) ratio is 7.43.